RecruitingNCT01432847
Ophthalmological
Retinitis Pigmentosa
Also known as RP, rod-cone dystrophy, pigmentary retinopathy
Retinitis Pigmentosa is a clinically and genetically heterogeneous group of inherited retinal dystrophies characterised by progressive degeneration of rod photoreceptors followed by cone involvement, leading to night blindness, constricting
ORPHA:791 ↗Gene RPGRGene RP1Gene RHOGene USH2A (multiple)Prevalence 1 per 3,500–4,000Onset Childhood to early adulthood (variable by subtype)Autosomal recessive, autosomal dominant, X-linked
48
studies recruiting now
as of 7 Sept 2026
319
studies registered in total
as of 7 Sept 2026
14
countries with a recruiting site
as of 7 Sept 2026
23 Jan 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT02617966
Rod and Cone Mediated Function in Retinal Disease
RecruitingPhase 1 / Phase 2NCT06789445
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
RecruitingNCT06092346
A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders
RecruitingNCT05589714
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 48 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Retinitis Pigmentosa study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: My Retina Tracker · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Retinitis Pigmentosa
Retinitis Pigmentosa is a clinically and genetically heterogeneous group of inherited retinal dystrophies characterised by progressive degeneration of rod photoreceptors followed by cone involvement, leading to night blindness, constricting visual fields, and eventual central vision loss. Over 90 causative genes have been identified, making RP the most genetically diverse of the inherited retinal diseases. It can occur as an isolated ocular condition or as part of syndromic conditions such as Usher syndrome and Bardet-Biedl syndrome.
Common clinical features
Night blindness (nyctalopia), often the first symptomProgressive peripheral visual field constriction (tunnel vision)Difficulty with dark adaptationBone-spicule pigmentation on fundus examinationAttenuated retinal blood vesselsWaxy pallor of the optic discReduced or extinguished rod ERG responsesLate-stage central vision loss
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
19 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Lutein
Phase 3Retinol (Arovit)
Phase 3Unoprostone Isopropyl (Rescula)
Phase 3Acetylcysteine (A-cys)
Phase 3Vitamin E (Aquasol e)
Phase 3Voretigene Neparvovec (Luxturna)
Phase 2/3Ciliary Neurotrophic Factor
Phase 2Levodopa (Bendopa)
+ 11 more in development
Before you apply
Things trial teams commonly ask about for Retinitis Pigmentosa. Not eligibility rules; those are set by each study.
- Genetic subtype is critical; trials are often gene-specific (e.g., RPGR-targeted for X-linked RP), so a confirmed genetic diagnosis via a retinal gene panel is essential before screening.
- Visual field area and ERG amplitude are standard eligibility benchmarks; retain copies of recent Goldmann or automated perimetry results.
- Syndromic RP (e.g., Usher syndrome) may have separate dedicated trials; confirm whether your diagnosis is isolated or syndromic before applying.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).